- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01355016
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
April 10, 2012 updated by: MicroDose Therapeutx, Inc
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 in Healthy Volunteers
The purpose of this study is to determine the range of single inhaled doses of a new dry powder product, MDT-637, that are safe and well-tolerated.
This includes monitoring effects on pulmonary function and determination of blood levels of MDT-637 following inhalation.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- West Coast Clinical Trials
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and/or surgically sterile or post-menopausal females (confirmed by FSH test); males must agree to practice barrier contraception until they are discharged from the study
- Willing to give written informed consent
- 18 to 50 years of age
- BMI of 19-30 Kg/m2
- Non-smoker (for at least 90 days prior to screening) and willing to abstain from smoking during the course of the study
- Good general health as determined by medical history, physical examination, ECG and clinical laboratory tests
- Willing to abstain from alcohol, caffeine, and xanthine-containing beverages for 24 hours prior to and 24 hours after dosing
Exclusion Criteria:
- Uncontrolled, clinically significant disease which in the opinion of the Principal Investigator and MDT would place the subject at risk through study participation or would confound the assessment of the safety of MDT-637
- Evidence of current or history of respiratory disease, including asthma, emphysema, chronic bronchitis, or cystic fibrosis
- History of significant nasal irritation from nasal inhalation of medication
- History of malignancy
- History of clinically significant alcohol or drug abuse
- Positive drug screen for drugs of abuse
- Positive test for HIV, Hepatitis B or Hepatitis C
- Allergy to lactose, or lactose intolerance
- Use of prescription medication within 14 days of Visit 2 or over-the-counter preparations, including dietary and herbal supplements, within 5 days of Visit 2
- Positive serum pregnancy test at Visit 1
- Inability to perform reproducible spirometry
- Abnormal FEV1, FVC, or FEV1/FVC (FEV1and FVC < 85% of predicted and variability of <5% or FEV1/FVC ratio < 0.7)
- Abnormal QTc interval at Visit 1(>450 msec in males or > 470 msec in females)
- Significant blood donation (or testing) in previous 8 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MDT-637
Active formulation
|
Inhaled doses of MDT-637 over a 24 hour period
|
Placebo Comparator: Placebo
Matched Placebo Comparator
|
Inhaled doses of MDT-637 over a 24 hour period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of 6 escalating doses of MDT-637 dry powder inhalation in healthy volunteers
Time Frame: Up to 22 days (including 14 day screening period)
|
Safety measurements include Clinical Laboratory Evaluations, Pulmonary Function Tests (Spirometry), ECG, Vital Signs, Physical Examination and Assessment of Adverse Events.
|
Up to 22 days (including 14 day screening period)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma pharmacokinetics for MDT-637 dry powder inhalation
Time Frame: Multiple plasma samples collected up to 24 hours post first dose
|
Plasma samples will be measured to determine MDT-637 pharmacokinetics as defined by Cmax
|
Multiple plasma samples collected up to 24 hours post first dose
|
Trough MDT-637 Nasal Concentration
Time Frame: 24 hours
|
Determination of MDT-637 concentration following nasal wash
|
24 hours
|
Plasma pharmacokinetics for MDT-637 dry powder inhalation
Time Frame: 24 hours
|
Plasma samples will be measured to determine MDT-637 pharmacokinetics as defined by Tmax
|
24 hours
|
Plasma pharmacokinetics of MDT-637 dry powder inhalation
Time Frame: 24 hours
|
Plasma samples will be measured to determine MDT-637 pharmacokinetics as defined by AUC
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
November 1, 2011
Study Completion (Actual)
November 1, 2011
Study Registration Dates
First Submitted
May 11, 2011
First Submitted That Met QC Criteria
May 16, 2011
First Posted (Estimate)
May 17, 2011
Study Record Updates
Last Update Posted (Estimate)
April 12, 2012
Last Update Submitted That Met QC Criteria
April 10, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDT-637-CP-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Syncytial Virus Infections
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus ImmunizationPuerto Rico, United States, Australia, Honduras, Mexico
-
EuBiologics Co.,LtdNot yet recruitingRespiratory Syncytial Virus Infections | Respiratory Syncytial Virus (RSV)
-
Clover Biopharmaceuticals AUS Pty LtdRecruitingRespiratory Syncytial Virus InfectionAustralia
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus InfectionJapan
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionChina
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus Infection
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus InfectionPuerto Rico, United States
-
PfizerCompletedRespiratory Syncytial Virus InfectionChina
-
Sanofi Pasteur, a Sanofi CompanyCompletedRespiratory Syncytial Virus InfectionHonduras, United States, Chile
-
Sanofi Pasteur, a Sanofi CompanyNot yet recruitingHealthy Volunteers | Respiratory Syncytial Virus Infection
Clinical Trials on MDT-637
-
MicroDose Therapeutx, IncCompletedDrug SafetyUnited States
-
MicroDose Therapeutx, IncCompleted
-
Medtronic Spinal and BiologicsWithdrawnPost-operation PainUnited States
-
Medtronic Spinal and BiologicsCompletedSciatica | Lumbosacral RadiculopathyUnited States
-
Rijnstate HospitalCompletedFrailty | Pre-operative | High-risk PatientNetherlands
-
Medtronic CardiovascularCompletedAortic Valve StenosisJapan
-
Medtronic CardiovascularCompletedAortic Valve StenosisJapan
-
Medtronic Cardiac SurgeryMedtronicActive, not recruiting
-
Nantes University HospitalUnknown
-
Grand Valley State UniversityMary Free Bed Rehabilitation HospitalCompletedHeadaches, TensionUnited States